CD8A and neoplasm: Despite being considered a “cold tumor” with a low tumor mutational burden, a positive correlation between the amount of tumor-infiltrating lymphocytes (TILs), in particular CD8+ cells, and favorable clinical outcome has been reported in EOC, suggesting that this disease might be sensitive to immunotherapeutic approaches, including adoptive T cell therapy (3–10).